Ropeginterferon + Ruxolitinib for Myelofibrosis

This trial tests whether adding a new drug, ropeginterferon alfa-2b, to the standard treatment of ruxolitinib is safe and effective for individuals with myelofibrosis, a type of blood cancer. Participants must have been on ruxolitinib for at least three months and possess a specific genetic mutation linked to their condition. The study targets individuals with an enlarged spleen who have been living with myelofibrosis or related conditions. As a Phase 1 trial, the research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new drug.

The trial requires participants to already be on a stable dose of ruxolitinib for at least 6 weeks before joining. If you are taking other medications that are prohibited, you may need to stop them for a period of at least five half-lives before starting the trial. The protocol does not specify all prohibited medications, so it's best to discuss your current medications with the trial team.

Research has shown that ropeginterferon alfa-2b is generally safe for people. In studies, it demonstrated promising safety results for patients with various conditions, including myelofibrosis. Most patients experience mild to moderate side effects. The most common side effects include changes in liver function and low white blood cell counts, occurring in about 20% of patients. These side effects are typical for treatments like interferons, which include ropeginterferon.

Researchers are excited about ropeginterferon alfa-2b for myelofibrosis because it offers a new approach by combining with the standard treatment, ruxolitinib. Unlike traditional therapies that primarily focus on controlling symptoms, ropeginterferon alfa-2b works by modulating the immune system, potentially targeting the disease process itself. This unique mechanism could offer patients improved outcomes and possibly alter the disease's progression, making it a promising addition to current treatment options.

Studies have shown that ropeginterferon alfa-2b can help treat certain blood conditions like polycythemia vera and early-stage myelofibrosis. One study demonstrated that ropeginterferon significantly improved blood cell counts and reduced spleen size in patients. Another study found that it improved blood counts in up to 82% of patients with early-stage primary myelofibrosis. These findings suggest that ropeginterferon can alleviate blood-related symptoms and slow disease progression. Patients have generally tolerated it well, making it a promising option for those with myelofibrosis. In this trial, participants will receive ropeginterferon alfa-2b combined with the standard treatment, ruxolitinib, to investigate its safety and tolerability.³⁶⁷⁸⁹